Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has received notification from the UK’s Medicines and Healthcare ...
Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S. clinical trials in 2026 to support a De Novo FDA application THE WOODLANDS, TX, Sept. 29, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results